Cargando…
Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999165/ https://www.ncbi.nlm.nih.gov/pubmed/31902065 http://dx.doi.org/10.1007/s12325-019-01204-0 |
| _version_ | 1783493934222147584 |
|---|---|
| author | Mu, Lifeng Zhou, Benhong |
| author_facet | Mu, Lifeng Zhou, Benhong |
| author_sort | Mu, Lifeng |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6999165 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69991652020-02-19 Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China Mu, Lifeng Zhou, Benhong Adv Ther Letter Springer Healthcare 2020-01-04 2020 /pmc/articles/PMC6999165/ /pubmed/31902065 http://dx.doi.org/10.1007/s12325-019-01204-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Letter Mu, Lifeng Zhou, Benhong Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China |
| title | Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China |
| title_full | Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China |
| title_fullStr | Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China |
| title_full_unstemmed | Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China |
| title_short | Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China |
| title_sort | letter: cost-effectiveness of alectinib for patients with untreated alk-positive non-small-cell lung cancer in china |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999165/ https://www.ncbi.nlm.nih.gov/pubmed/31902065 http://dx.doi.org/10.1007/s12325-019-01204-0 |
| work_keys_str_mv | AT mulifeng lettercosteffectivenessofalectinibforpatientswithuntreatedalkpositivenonsmallcelllungcancerinchina AT zhoubenhong lettercosteffectivenessofalectinibforpatientswithuntreatedalkpositivenonsmallcelllungcancerinchina |